Radius Health announces publication of elacestrant clinical trial data

The Menarini Group and Radius Health "announce that data from the pivotal phase 3 EMERALD clinical trial evaluating elacestrant as a monotherapy vs. standard of care for the treatment of ER+/HER2- advanced or metastatic breast cancer were published in the Journal of Clinical Oncology. Elacestrant is the first oral selective estrogen receptor degrader demonstrating a significant improvement in PFS vs. SOC with manageable safety in a phase 3 trial for patients with ER-positive/HER2-negative advanced breast cancer. Among the 477 patients enrolled in the trial, 239 received elacestrant. Of the 165 patients who received fulvestrant, all were pretreated with AI during the treatment for metastatic disease except n=6 who received fulvestrant. Of the 73 who received AI, all were pretreated with fulvestrant except n=4. Primary endpoints were PFS by blinded independent central review (IRC) in all patients and patients with detectable ESR1 mutations. Elacestrant significantly reduced the risk of disease progression or death by 30% in all patients and by 45% in patients with ESR1 mutation."